Currently, ADCs targeting colorectal cancer are mainly monoclonal antibody ADCs, with primary targets including human epidermal growth receptor 2 (HER2), guanylyl cyclase C (GCC), mesothelin, and carcinogenic antigen-related cell adhesion molecule 5 (CEACAM5), and so on [49–52]. This evidence concerns the gene ERBB2 and colorectal cancer.